

# **Anti-diarrheal agents**

**Dr/ Heba Ahmed Hassan**

**associate professor of clinical pharmacology faculty of medicine  
mutah university**

# Common Causes of Sudden or Chronic Diarrhea


## Sudden Diarrhea



Food poisoning



Traveler's diarrhea



Stomach flu

## Chronic Diarrhea



Celiac disease



Food intolerance/  
allergy



Milk/soy protein  
intolerance



IBS



Medication



# **Pathophysiology of diarrhea**

- **Increase the GIT motility**
- **Increase the secretions and decrease the absorption of fluids and electrolytes -----which lead to Na , water and electrolyte disturbance**
- **Infection**

# Treatment of diarrhea

**A- Rehydration ( oral or I.V fluids)**

**B- Anti-infective agents ( according to infective organism)**

**C- Non-antimicrobial antidiarrheal agents**

**D-Treatment of inflammatory bowel diseases**



## C- Non-antimicrobial antidiarrheal agents:

should not be used in patients with

1-bloody diarrhea

2-high fever

3- systemic toxicity

because of the risk of worsening underlying condition.

N.B: you should stop if worsen despite therapy

## They are classified as follow:

**1-Anti-motility agents**

**2-GIT protective & adsorbents agents**

**3-Agents which modify fluid and electrolyte transport**

**4-Others**

-Bile salts binding resins (cholestyramine)



# 1- Antimotility agents

**A-Anticholinergic** ( they reduce the motility and secretions of the GIT as atropine and propantheline)

**B-Opioid agonists** (they activate  $\mu$  receptors on enteric neurons  $\rightarrow$   $\uparrow$   $K^+$  efflux  $\rightarrow$  hyper polarization  $\rightarrow$  inhibit Ach release  $\rightarrow$   $\downarrow$  motility  $\rightarrow$   $\uparrow$  transit time  $\rightarrow$   $\uparrow$  absorption of fluid & electrolyte.

## Diphenoxylate:


- Readily absorbed → systemic effects (sedation & addiction).
- **Lomotil:** Diphenoxylate + atropine .



## Loperamide (Imodium):

- Slow & incomplete absorption.
- Not crossing B.B.B.
- Relatively selective action on G.I.T.





• **Side effects:**

- Dry mouth, dizziness, headache, abdominal cramps, nausea and vomiting.
- Paralytic ileus.

• **Contraindications:**

- Chronic ulcerative colitis.
- Young children.
- Acute bacillary & amoebic dysentery.

## 2. GIT protective & adsorbents agents:

- ❖ Kaolin.
- ❖ Pectin.
- ❖ Chalk.
- ❖ Methylcellulose.
- ❖ Charcoal.

## Kaopectate (kaolin & pectin):

- 1.2-1.5 g after each loose bowel

movement (maximum: 9g /d).

- Not absorbed (**no adverse effects**).

- Should not be taken within 2 hours of

other medication.



# 3- Agents which modify fluid and electrolyte transport:

Reduce secretion & or stimulate absorption of fluids

## Bismuth subsalicylate

[Bi<sup>3+</sup> (antibacterial) + salicylate (inhibit PG)]:

- Coat ulcer.
- ↓ Stool frequency & liquidity in acute infectious diarrhea, due to salicylate inhibition of intestinal PG & chloride secretion.




- ✓ Bismuth has **direct antimicrobial effects** & binds enterotoxins.
- ✓ Prevent & treat **traveler's diarrhea**
- ✓ Bismuth compound have **direct antimicrobial** activity **against H pylori.**
- ✓ **Dose:** Pepto-Bismol; 2 tablets (520mg) every 30 min.



# Chronic inflammatory bowel disease (IBD) includes: (ulcerative colitis & Crohn's disease).

Drugs used in treatment of IBD include:

- **Corticosteroids:** prednisolone.
- **Immunosuppressive agents:** azathioprine , 6mercaptopurine.
- **Aminosalicylates.**



# Aminosalicylates

Up to 80% of unformulated, aqueous 5-ASA is absorbed from the small intestine & does not reach the distal small bowel or colon in appreciable quantities.



## □ Azo compounds:

□ 5-ASA bound by an azo (N=N) bond to an inert compound or to another 5-ASA molecule.

□ Azo markedly reduces absorption of the parent drug from the small intestine.

□ In terminal ileum & colon, bacteria cleave the azo bond by **azo reductase**, releasing the active 5-ASA.

- **Sulfasalazine:** (5-ASA “Active moiety” + Sulfapyridine “side effects”).
- **Olsalazine:** (two molecules of 5-ASA).
- **Balsalazide:** (5-ASA + 4-aminobenzol- $\beta$ -alanine).



## □ Mesalamine compounds

Package of 5-ASA itself in various ways to deliver it to different segments of the small or large bowel.

**Pentasa:** contains timed-release microgranules that release 5-ASA throughout the small intestine.

**Asacol:** has 5-ASA coated in pH-sensitive resin that dissolves at pH 7 (the pH of the distal ileum & proximal colon).

**Rowasa** (enema formulations) &

**Canasa** (suppositories): To deliver high concentration of 5-ASA to the rectum & sigmoid colon.



## Mechanism of action:

- ✓ 5-ASA inhibits inflammatory mediators derived from both the cyclooxygenase & lipooxygenase pathways.
- ✓ Interferes with the production of inflammatory cytokines.
- ✓ Inhibits the activity of nuclear factor- $\kappa_B$  (NF- $\kappa_B$ ), an important transcription factor for pro-inflammatory cytokines.
- ✓ Inhibits cellular functions of natural killer cells, mucosal lymphocytes, and macrophages.
- ✓ It may scavenge reactive oxygen metabolites.

# Pharmacokinetics:

## Mesalamine:

- 20-30% of 5-ASA is absorbed.
- 5-ASA undergoes N-acetylation in the liver and gut epithelium.
- Metabolite is excreted by the kidneys.

## Sulfasalazine

- 10% is absorbed.
- After azoreductase, >85% of sulfapyridine is absorbed.
- Sulfapyridine undergoes hepatic metabolism.
- Metabolite is excreted by the kidney.

## Balsalazide:

- <1% is absorbed.
- After azoreductase, small amount of systemic absorption occurs.

## Therapeutic uses:

1. First-line agents for treatment of mild to moderate active ulcerative colitis
2. Crohn's disease involving the small bowel *mesalamine* compounds, which release 5-ASA in the small intestine, have advantage over azo compounds

3. Ulcerative colitis or Crohn's colitis that extends to the proximal colon, both azo & mesalamine compounds are useful.

3. Ulcerative colitis or Crohn's disease confined to the rectum or distal colon, suppositories or enema are useful.

## Adverse effects:

**Sulfasalazine** (→ sulfapyridine) has high incidence of side effects , >40% cannot tolerate therapeutic doses:

1. GIT upset, headache, arthralgia, bone marrow suppression & malaise
2. Hypersensitivity ( fever, exfoliative dermatitis, pancreatitis, pneumonitis, hemolytic anemia, pericarditis, or hepatitis).
3. Reversible oligospermia
4. Impairs folate absorption



## *Other aminosalicylate formulations*

Are well tolerated:

*Olsalazine* may cause secretory diarrhea (10%).

Hypersensitivity (rare).

Interstitial nephritis (rare, high doses of *mesalamine*).



THANK YOU